# Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma

Source: https://onco.cc/trials/nct06829771/  
OnCo record `nct06829771` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of TQB2825 in diffuse large b-cell lymphoma, run by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., now recruiting.

## Summary

Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma is a phase 1/2 interventional study registered as NCT06829771 by Chia Tai Tianqing Pharmaceutical Group Co., Ltd., with 90 participants planned, started 2025-04-23 and due to reach its primary completion in 2026-05. Interventions recorded: TQB2825 injection +R-CHOP regimen, TQB2825 injection + GemOx. Conditions listed: Diffuse Large B Cell Lymphoma. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06829771
- Phase: 1/2
- Setting: Phase Ib/II Clinical Trial of TQB2825 Injection Combined Immunochemotherapy in Subjects With Diffuse Large B Cell Lymphoma
- Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Enrolled: 90

## Sources

- ClinicalTrials.gov NCT06829771: https://clinicaltrials.gov/study/NCT06829771

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- drugs: [TQB2825](https://onco.cc/drugs/tqb2825/)
- companies: [Sino Biopharmaceutical (Chia Tai Tianqing)](https://onco.cc/companies/sino-biopharm/)

---
JSON: https://onco.cc/api/v1/entities/nct06829771.json